city New Delhi India covid-19 patient symptomatic city New Delhi India

DCGI nod to Hetero Labs' Favipiravir for treating mild-to-moderate Covid-19

Reading now: 595
www.livemint.com

₹2,640 per pack New Delhi, Sep 25 (PTI) Drug firm Hetero on Friday said it has launched a pack of its generic oral antiviral drug-- Favivir 800/200-- for the treatment of mild-to-moderate symptomatic COVID-19 patients in India.Favivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at ₹2,640 per pack, Hetero said in a statement.The higher strength of Favipiravir 800 mg by the company has been approved by the Drug Controller General of India (DCGI).

The product will be marketed and distributed by Hetero Healthcare Ltd, it added."The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA